Noveome Biotherapeutics Inc.

In this @DDNews interview, our own Larry Brown discusses recent preclinical data that showed the neuroprotective potential of our biologic, ST266. Read the article from @KelseyKaustinen to learn more about its potential for treating diseases in ophthalmology, neurology, dermatology: http://ow.ly/HGQx50DQAbP

We are proud to announce the appointment of Christopher Velis to our Board of Directors. Mr. Velis' extensive experience with innovative medical technologies, will provide significant value to Noveome. Welcome Chris, we are honored to have you! https://www.businesswire.com//Noveome-Biotherapeutics-Inc.

Our very own Larry Brown, Sc.D., Executive Vice President and Chief Scientific Officer at Noveome, is scheduled to present during the upcoming Annual Neurodegenerative Drug Development Summit. Larry's presentation will cover the evolution of Noveome’s neuroprotection research and development program from cell therapy to secretome. http://ow.ly/hltQ50DGwPl

We are thrilled to announce a new Cooperative Research and Development Agreement ( CRADA) with Walter Reed Army Institute of Research (WRAIR). The research will test the effects of ST266, in animal models of closed Traumatic Brain Injury (TBI). https://www.businesswire.com//Noveome-Biotherapeutics-Inc.

We are proud to announce that our Chief Scientific Officer, Larry Brown, Sc.D. and Chief Medical Officer, David Steed, M.D. will present an update on our Retinal and Optic Nerve Disease Clinical Program, at the Glaucoma Research Foundation's 10th Annual Glaucoma 360 Meeting. Thank you both for sharing information on our exciting and groundbreaking work. https://www.businesswire.com//Noveome-Biotherapeutics-Inc. #biotechnology #biotech #glaucoma360 #glaucomaawareness #noveome #pittsburghbiotech

We are honored to announce the appointment of Ronald Poropatich, M.D. , M.S. to our Board of Directors. Dr. Poropatich brings vast medical knowledge and experience from a long career in the U.S. Army and the University of Pittsburgh. Welcome to Noveome! #noveome #biotechnology #Pittsburgh #boardofdirectors